Histone deacetylase inhibitors in hematological malignancies and solid tumors

다국어 초록 (Multilingual Abstract)

Histone deacetylase (HDAC) inhibitors areemerging as promising anticancer drugs. Because aberrantactivity and expression of HDACs have been implicated invarious cancer types, a wide range of HDAC inhibitors arebeing investigated as anticancer agents. Furthermore, dueto the demonstrable anticancer activity in both in vitro andin vivo studies, numerous HDAC inhibitors have undergonea rapid phase of clinical development in variouscancer types, either as a monotherapy or in combinationwith other anticancer agents. Although preclinical trialsshow that HDAC inhibitors have a variety of biologicaleffects across multiple pathways, including regulation ofgene expression, inducing apoptosis and cell cycle arrest,inhibiting angiogenesis, and regulation of DNA damageand repair, the mechanism by which the clinical activity ismediated remains unclear. Understanding the mechanismsof anticancer activity of HDAC inhibitors is essential notonly for rational drug design for targeted therapies, but forthe design of optimized clinical protocols. This paperdescribes the links between HDACs and cancer, and theunderlying mechanisms of action of HDAC inhibitorsagainst hematological malignancies and solid tumors.
Further, this review presents the clinical outcomes ofvorinostat, romidepsin, and belinostat, which are approvedby the United States Food and Drug Administration for thetreatment of lymphomas.

참고문헌 (Reference)

1 Hitomi, T., "p15(INK4b)in HDAC inhibitor-induced growth arrest" 554 : 347-350, 2003

2 Traynor, A.M., "Vorinostat(NSC# 701852)in patients with relapsed nonsmall cell lung cancer : A Wisconsin Oncology Network phase II study" 4 : 522-526, 2009

3 Bradley, D., "Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy(National Cancer Institute Trial 6862) : Trial results and interleukin-6 analysis : A study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium" 115 : 5541-5549, 2009

4 Halkidou, K., "Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer" 59 : 177-189, 2004

5 Hayashi, A, "Type-specific roles of histone deacetylase(HDAC)overexpression in ovarian carcinoma : HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin" 127 : 1332-1346, 2010

6 Jin, Y.H., "Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation" 279 : 29409-29417, 2004

7 Gaughan, L., "Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor" 277 : 25904-25913, 2002

8 Ropero, S., "The role of histone deacetylases(HDACs)in human cancer" 1 : 19-25, 2007

9 Hutt, D.M., "The histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibition" 9 : e106224-, 2014

10 Zhang, X.D, "The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells" 3 : 425-435, 2004

11 Ruefli, A.A., "The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species" 98 : 10833-10838, 2001

12 Fischle, W, "The emerging role of class II histone deacetylases" 79 : 337-348, 2001

13 Firestein, R., "The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth" 3 : e2020-, 2008

14 Ashkenazi, A., "Targeting death and decoy receptors of the tumour-necrosis factor superfamily" 2 : 420-430, 2002

15 Zheng, G, "Sumoylation and acetylation play opposite roles in the transactivation of PLAG1 and PLAGL2" 280 : 40773-40781, 2005

16 Konstantinopoulos, P.A, "Suberoylanilide hydroxamic acid(SAHA)enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer" 133 : 599-606, 2014

17 Younes, A., "Suberoylanilide hydroxamic acid suppresses inflammationinduced neovascularization" 92 : 879-885, 2014

18 Zhou, H, "Suberoylanilide hydroxamic acid suppresses inflammation-induced neovascularization" 92 : 879-885, 2014

19 Richon, V.M., "Second generation hybrid polar compounds are potent inducers of transformed cell differentiation" 93 : 5705-5708, 1996

20 Yuan, Z.L, "STAT3 dimerization regulated by reversible acetylation of a single lysine residue" 307 : 269-273, 2005

21 Gobinet, J., "SHP represses transcriptional activity via recruitment of histone deacetylases" 44 : 6312-6320, 2005

22 Ungerstedt, J.S., "Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors" 102 : 673-678, 2005

23 Lin, R.J., "Role of the histone deacetylase complex in acute promyelocytic leukaemia" 391 : 811-814, 1998

24 Coiffier, B., "Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy" 30 : 631-636, 2012

25 Kim, S.H., "Regulation of the HIF-1alpha stability by histone deacetylases" 17 : 647-651, 2007

26 Martı ´nez-Balba ´s, M.A., "Regulation of E2F1 activity by acetylation" 19 : 662-671, 2000

27 Osada, H, "Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients" 112 : 26-32, 2004

28 Lynch Jr., D.R., "QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat : A case report and review of the literature" 19 : 434-438, 2012

29 Straus, S.M, "Prolonged QTc interval and risk of sudden cardiac death in a population of older adults" 47 : 362-367, 2006

30 Marquard, L., "Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma" 53 : 267-277, 2008

31 Olsen, E.A., "Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma" 25 : 3109-3115, 2007

32 Molife, L.R., "Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor(HDACi)romidepsin in metastatic castration-resistant prostate cancer(CRPC)" 21 : 109-113, 2010

33 Blumenschein Jr., G.R, "Phase II trial of the histone deacetylase inhibitor vorinostat(Zolinza, suberoylanilide hydroxamic acid, SAHA)in patients with recurrent and/or metastatic head and neck cancer" 26 : 81-87, 2008

34 Haigentz Jr., M., "Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer" 48 : 1281-1288, 2012

35 Mackay, H.J., "Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary(LMP)ovarian tumours" 46 : 1573-1579, 2010

36 Whitehead, R.P., "Phase II trial of romidepsin(NSC-630176)in previously treated colorectal cancer patients with advanced disease : A Southwest Oncology Group study(S0336)" 27 : 469-475, 2009

37 Kirschbaum, M., "Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin’s lymphoma and mantle cell lymphoma" 29 : 1198-1203, 2011

38 Cashen, A, "Phase II study of the histone deacetylase inhibitor belinostat(PXD101)for the treatment of myelodysplastic syndrome(MDS)" 91 : 33-38, 2012

39 Otterson, G.A, "Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer(Cancer and Leukemia Group B 30304)" 5 : 1644-1648, 2010

40 Ramalingam, S.S., "Phase II study of belinostat(PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma" 4 : 97-101, 2009

41 Giaccone, G., "Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors" 29 : 2052-2059, 2011

42 Piekarz, R.L., "Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma" 27 : 5410-5417, 2009

43 Kelly, W.K., "Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer" 23 : 3923-3931, 2005

44 Duvic, M., "Phase 2 trial of oral vorinostat(suberoylanilide hydroxamic acid, SAHA)for refractory cutaneous T-cell lymphoma(CTCL)" 109 : 31-39, 2006

45 Garcia-Manero, G., "Phase 1 study of the histone deacetylase inhibitor vorinostat(suberoylanilide hydroxamic acid [SAHA])in patients with advanced leukemias and myelodysplastic syndromes" 111 : 1060-1066, 2008

46 Sandor, V, "P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228" 83 : 817-825, 2000

47 Kawai, H., "Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha" 107 : 353-358, 2003

48 Mal, A., "MyoD is functionally linked to the silencing of a muscle-specific regulatory gene prior to skeletal myogenesis" 100 : 1735-1739, 2003

49 Seo, S.Y., "Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug discovery" 35 : 197-200, 2012

50 Strevel, E.L., "Molecularly targeted oncology therapeutics and prolongation of the QT interval" 25 : 3362-3371, 2007

51 Gregoretti, I.V., "Molecular evolution of the histone deacetylase family : Functional implications of phylogenetic analysis" 338 : 17-31, 2004

52 Mwakwari, S.C., "Macrocyclic histone deacetylase inhibitors" 10 : 1423-1440, 2010

53 Fournel, M, "MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo" 7 : 759-768, 2008

54 Fraga, M.F, "Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer" 37 : 391-400, 2005

55 Ho ¨rlein, A.J., "Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor corepressor" 377 : 397-404, 1995

56 Yang, W.M., "Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family" 272 : 28001-28007, 1997

57 Sutheesophon, K., "Involvement of the tumor necrosis factor(TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide(FK228)" 203 : 387-397, 2005

58 Bertrand, P., "Inside HDAC with HDAC inhibitors" 45 : 2095-2116, 2010

59 Zhao, Y., "Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim" 102 : 16090-16095, 2005

60 Insinga, A., "Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway" 11 : 71-76, 2005

61 Lee, Y.M., "Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity" 300 : 241-246, 2003

62 Bali, P., "Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90 : A novel basis for antileukemia activity of histone deacetylase inhibitors" 280 : 26729-26734, 2005

63 Song, J., "Increased expression of histone deacetylase 2 is found in human gastric cancer" 113 : 264-268, 2005

64 Hu, E., "Identification of novel isoform-selective inhibitors within class I histone deacetylases" 307 : 720-728, 2003

65 Peart, M.J., "Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors" 102 : 3697-3702, 2005

66 Johnstone, R.W, "Histone-deacetylase inhibitors : Novel drugs for the treatment of cancer" 1 : 287-299, 2002

67 de Ruijter, A.J., "Histone deacetylases(HDACs) : Characterization of the classical HDAC family" 370 : 737-749, 2003

68 Kim, M.S, "Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes" 7 : 437-443, 2001

69 Marks, P., "Histone deacetylases and cancer : Causes and therapies" 1 : 194-202, 2001

70 Park,S.Y, "Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer" 25 : 1677-1681, 2011

71 Weichert, W., "Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy" 98 : 604-610, 2008

72 Montgomery, R.L., "Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility" 21 : 1790-1802, 2007

73 Geng, L., "Histone deacetylase(HDAC)inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer" 66 : 11298-11304, 2006

74 Qiu, L., "Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells" 11 : 2069-2083, 2000

75 Sawa, H., "Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the Bcl-2-related protein Bad" 18 : 109-114, 2001

76 Burgess, A., "Histone deacetylase inhibitors specifically kill nonproliferating tumour cells" 23 : 6693-6701, 2004

77 Chen, C.S., "Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation" 67 : 5318-5327, 2007

78 Fath, D.M., "Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha" 281 : 13612-13619, 2006

79 Munshi, A., "Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity" 11 : 4912-4922, 2005

80 Kong, X., "Histone deacetylase inhibitors induce VHL and ubiquitinindependent proteasomal degradation of hypoxia-inducible factor 1alpha" 26 : 2019-2028, 2006

81 Rosato, R.R., "Histone deacetylase inhibitors : Insights into mechanisms of lethality" 9 : 809-924, 2005

82 Yamashita, Y, "Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells" 103 : 572-576, 2003

83 Koprinarova, M., "Histone deacetylase inhibitor sodium butyrate enhances cellular radiosensitivity by inhibiting both DNA nonhomologous end joining and homologous recombination" 10 : 970-977, 2011

84 Richon, V.M, "Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation" 97 : 10014-10019, 2000

85 Wang, J.C., "Histone deacetylase in chronic lymphocytic leukemia" 81 : 325-329, 2011

86 Oehme, I., "Histone deacetylase 8 in neuroblastoma tumorigenesis" 15 : 91-99, 2009

87 Kato, H., "Histone deacetylase 7 associates with hypoxia-inducible factor 1alpha and increases transcriptional activity" 279 : 41966-41974, 2004

88 Li, D., "Histone deacetylase 6 and cytoplasmic linker protein 170 function together to regulate the motility of pancreatic cancer cells" 5 : 214-223, 2014

89 Atsumi, A., "Histone deacetylase 3(HDAC3)is recruited to target promoters by PML–RARalpha as a component of the N-CoR co-repressor complex to repress transcription in vivo" 345 : 1471-1480, 2006

90 Ozawa, Y., "Histone deacetylase 3 associates with and represses the transcription factor GATA-2" 98 : 2116-2123, 2001

91 Gui, C.Y, "Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1" 101 : 1241-1246, 2004

92 Norton, V.G., "Histone acetylation reduces nucleosome core particle linking number change" 57 : 449-457, 1989

93 Grunstein, M., "Histone acetylation in chromatin structure and transcription" 389 : 349-352, 1997

94 Kouzarides, T., "Histone acetylases and deacetylases in cell proliferation" 9 : 40-48, 1999

95 Ouaı ¨ssi, M., "High histone deacetylase 7(HDAC7)expression is significantly associated with adenocarcinomas of the pancreas" 15 : 2318-2328, 2008

96 Kovacs, J.J., "HDAC6 regulates Hsp90 acetylation and chaperonedependent activation of glucocorticoid receptor" 18 : 601-607, 2005

97 Serrador, J.M., "HDAC6 deacetylase activity links the tubulin cytoskeleton with immune synapse organization" 20 : 417-428, 2004

98 Feng, G.W., "HDAC5 promotes cell proliferation in human hepatocellular carcinoma by up-regulating Six1 expression" 18 : 811-816, 2014

99 Milde, T., "HDAC5 and HDAC9 in medulloblastoma : Novel markers for risk stratification and role in tumor cell growth" 16 : 3240-3252, 2010

100 Jung, K.H., "HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins" 113 : 2167-2177, 2012

101 Deubzer, H.E., "HDAC11 is a novel drug target in carcinomas" 132 : 2200-2208, 2013

102 Xie, H.J., "HDAC1 inactivation induces mitotic defect and caspase independent autophagic cell death in liver cancer" 7 : e34265-, 2012

103 Stypula-Cyrus, Y., "HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure" 8 : e64600-, 2013

104 Whittaker, S.J., "Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma" 28 : 4485-4491, 2010

105 Furumai, R., "FK228(depsipeptide)as a natural prodrug that inhibits class I histone deacetylases" 62 : 4916-4921, 2002

106 Mann, B.S, "FDA approval summary : Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma" 12 : 1247-1252, 2007

107 Minamiya, Y., "Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung" 74 : 300-304, 2011

108 Vansteenkiste, J., "Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or nonsmall cell lung cancer" 26 : 483-488, 2008

109 Amann, J.M., "ETO, a target of t(8;21)in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain" 21 : 6470-6483, 2001

110 Chen, L.f., "Duration of nuclear NF-kappaB action regulated by reversible acetylation" 293 : 1653-1657, 2001

111 Cha, T.L., "Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2–M arrest and apoptosis of renal cancer cells" 15 : 840-850, 2009

112 "Drugs@FDA"

113 "Drugs. Romidepsin"

114 "Drugs. Belinostat"

115 Wolbrette, D., "Drugs that cause torsades de pointes and increase the risk of sudden cardiac death" 6 : 379-384, 2004

116 El-Khoury, V, "Disruption of autophagy by the histone deacetylase inhibitor MGCD0103 and its therapeutic implication in B-cell chronic lymphocytic leukemia" 28 : 1636-1646, 2014

117 Mu ¨ller, B.M., "Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer—Overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression" 13 : 215-, 2013

118 Moreno, D.A., "Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia" 150 : 665-673, 2010

119 Khan, N., "Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors" 409 : 581-589, 2008

120 Luo, J, "Deacetylation of p53 modulates its effect on cell growth and apoptosis" 408 : 377-381, 2000

121 Bakkenist, C.J., "DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation" 421 : 499-506, 2003

122 Decroos, C, "Compromised structure and function of HDAC8 mutants identified in Cornelia de Lange Syndrome spectrum disorders" 9 : 2157-2164, 2014

123 Gao, L., "Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family" 277 : 25748-25755, 2002

124 Quint, K, "Clinical significance of histone deacetylases 1, 2, 3, and 7 : HDAC2 is an independent predictor of survival in HCC" 459 : 129-139, 2011

125 Qian, D.Z, "Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha" 66 : 8814-8821, 2006

126 Verdin, E., "Class II histone deacetylases : Versatile regulators" 19 : 286-293, 2003

127 Bertos, N.R., "Class II histone deacetylases : Structure, function, and regulation" 79 : 243-252, 2001

128 Fritzsche, F.R., "Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer" 8 : 381-, 2008

129 Adams, H., "Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin’s lymphoma" 14 : 577-584, 2010

130 Weichert, W., "Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer : Specific role of class I histone deacetylases in vitro and in vivo" 14 : 1669-1677, 2008

131 Bantscheff, M., "Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes" 29 : 255-265, 2011

132 Bradner, J.E., "Chemical phylogenetics of histone deacetylases" 6 : 238-243, 2010

133 Bates, S.E, "Challenges of evaluating the cardiac effects of anticancer agents" 12 : 3871-3874, 2006

134 Shah, M.H., "Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors" 12 : 3997-4003, 2006

135 Piekarz,R.L., "Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma" 12 : 3762-3773, 2006

136 Zgouras, D., "Butyrate impairs intestinal tumor cell-induced angiogenesis by inhibiting HIF-1alpha nuclear translocation" 300 (300): 832-838, 2003

137 Zhang, Y., "Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis" 13 : 129-140, 2006

138 "BELIEF study"

139 Weichert, W., "Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer : A retrospective analysis" 9 : 139-148, 2008

140 Burz, C., "Apoptosis in cancer : Key molecular signaling pathways and therapy targets" 48 : 811-821, 2009

141 Heltweg, B., "Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes" 66 : 4368-4377, 2006

142 Bagnes, C., "Antineoplastic chemotherapy induced QTc prolongation" 5 : 93-96, 2010

143 Bolden, J.E., "Anticancer activities of histone deacetylase inhibitors" 5 : 769-784, 2006

144 Pe ´rez-Perarnau, A., "Analysis of apoptosis regulatory genes altered by histone deacetylase inhibitors in chronic lymphocytic leukemia cells" 6 : 1228-1235, 2011

145 Noh, E.J., "An HDAC inhibitor, trichostatin A, induces a delay at G2/M transition, slippage of spindle checkpoint, and cell death in a transcriptiondependent manner" 378 : 326-331, 2009

146 Watamoto, K, "Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation" 22 : 9176-9184, 2003

147 Gelmetti, V., "Aberrant recruitment of the nuclear receptor corepressor–histone deacetylase complex by the acute myeloid leukemia fusion partner ETO" 18 : 7185-7191, 1998

148 Ropero, S, "A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition" 38 : 566-569, 2006

149 Mal, A., "A role for histone deacetylase HDAC1 in modulating the transcriptional activity of MyoD : Inhibition of the myogenic program" 20 : 1735-1739, 2001

150 Luu, T.H., "A phase II trial of vorinostat(suberoylanilide hydroxamic acid)in metastatic breast cancer : A California Cancer Consortium study" 14 : 7138-7142, 2008

151 Modesitt, S.C., "A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma : A Gynecologic Oncology Group study" 109 : 182-186, 2008

152 Stadler, W.M, "A phase II study of depsipeptide in refractory metastatic renal cell cancer" 5 : 57-60, 2006

153 Iwamoto, F.M., "A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma : North American Brain Tumor Consortium Study 03-03" 13 : 509-516, 2011

154 Lassen, U., "A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours" 103 : 12-17, 2010

155 Steele, N.L., "A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors" 14 : 804-810, 2008

156 Kim, M.K., "A novel hydroxamic acid derivative, MHY218, induces apoptosis and cell cycle arrest through downregulation of NF-jB in HCT116 human colon cancer cells" 44 : 256-264, 2014

157 Ogura, M., "A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma" 165 : 768-776, 2014

158 Curran,M.E., "A molecular basis for cardiac arrhythmia : HERG mutations cause long QT syndrome" 80 : 795-803, 1995

159 Foss, F., "A Phase II trial of Belinostat(PXD101)in patientswith relapsed or refractory peripheral or cutaneous T-cell lymphoma(Abstract)" 2014